PAULA NJERU
ID:
|
Utility of An Epilepsy Self-Management And Resilience Technical (SMART) APP for Adolescents and Young Adults
REFNo: HS3799ES
To identify specific improvements for the APP that will make it more useful for AWE and young adults.,To understand aspects of the APP that AWE and young adults derive the greatest benefit from.,To understand the perspectives of adolescents and young adults with epilepsy about using the SMART APP. ,To characterize the experiences of adolescents and young adults with epilepsy while using the SMART APP, pinpoint the essential elements of the APP that adolescents and young adults with epilepsy find most advantageous, and propose specific enhancements to further improve the APP,
|
Kenya |
2024-06-05 17:45:41 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Richard Rwabuhinga
ID:
|
Influence of Competency and performance on Employability in Uganda; A case study of Mountains of the Moon and United Pentecostal Universities
REFNo: HS3058ES
4. The establish the impact of competencies on interpersonal skills of graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda,3. To find out the influence of competence on problem solving skills of education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,2. To establish the influence of competence on communication skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,1. To establish the influence of competence on academic skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,
|
Uganda |
2024-06-05 17:44:09 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB
REFNo: HS3834ES
1.2 Secondary Objectives 1.2.1 Phase 2a and 2b: To evaluate the proportion of participants with a quantifiable RS ratio after therapeutic vaccination with ID93 + GLA-SE compared to placebo. 1.2.2 Phase 2a: To evaluate the kinetics of cellular immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.3 Phase 2a: To evaluate the kinetics of humoral immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.4 Phase 2a: To evaluate innate immune changes in response to ID93 + GLA-SE through 2 weeks post second dose of study product. 1.2.5 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE, to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, in subgroups defined by: Hard-to-treat phenotype and not hard-to-treat phenotype, where hard-to-treat phenotype is defined as smear Grade ≥3 and cavitary disease on chest radiograph at TB diagnosis.1.3 Exploratory Objectives 1.3.1 Phase 2a: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to: • The safety and immunogenicity of ID93 + GLA-SE in participants living with and without HIV. • The quantitative RS ratio at time points relative to vaccination and TB treatment as indicated in the Schedule of Evaluations (SOE). • The magnitude and quality of immune responses with respect to the composition of the intestinal microbiota. 1.3.2 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, adjusted for • Pharmacokinetics (PK) assessments of first-line TB drugs (exposure) during TB treatment as per the SOE. • Levels of participant adherence to standard of care (SOC) TB treatment measured using self-reporting and urine acetyl-isoniazid (AcINH) from start to end of TB treatment. 1.3.3 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, stratified by bacterial burden at start of TB treatment. 1.3.4 Phase 2a and 2b: To develop the composite predictive model of TB drug response by using measures of adherence, drug exposure (PK), immune response, gut microbiota, and participant phenotype. 1.3.5 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to proportion of participants with sputum culture conversion at baseline at time of randomization and at Step 2, Days 30, 120, and 150, which are approximately 2, 5, and 6 months after start of TB treatment. 1.3.6 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to cumulative relapse from end of TB treatment up to end of study follow-up, that is, Step 2, Days 420, 450, 480, and 510, for Groups 1, 2, 3 (&5), and 4 (&5), respectively. 1.3.7 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to lung function and health-related quality of life, as measured by spirometry and the St. George’s Respiratory Questionnaire. 1.3.8 Phase 2a and 2b: To compare the within-person change in lung function tests over time from the first dose of therapeutic vaccination with ID93 + GLA-SE to placebo. 1.3.9 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to resolution of transcriptomic biomarkers of TB disease. 1.3.10 Phase 2b: To identify correlates of protection for unfavorable TB outcomes. 1.3.11 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes among participants living with and without HIV. 1.3.12 Phase 2a and 2b: To conduct analyses related to furthering the understanding of TB, HIV, immunology, vaccines, and clinical trial conduct.,1.1 Primary Objectives 1.1.1 Phase 2a and 2b: To evaluate safety of a two-dose ID93 + GLA-SE vaccine regimen administered 60 days apart on Step 2, Days 0 and 60, with TB treatment administered, at approximately: 1.1.1.1 Months 4 and 6 after start of TB treatment (Group 1) 1.1.1.2 Months 3 and 5 after start of TB treatment (Group 2) 1.1.1.3 Months 2 and 4 after start of TB treatment (Group 3 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.1.4 Months 1 and 3 after start of TB treatment (Group 4 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.2 Phase 2a and 2b: To determine if therapeutic vaccination with ID93 + GLA-SE will increase the magnitude of vaccine-specific cellular responses compared to placebo at 2 weeks post second dose of study product. 1.1.3 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes (treatment failure, TB recurrence, or death due to TB) at Day 540 after study entry, which is approximately 18 months after start of TB treatment (Group 5 combined with either Group 3 or Group 4, depending on which vaccination schedule is selected for Group 5).,
|
Uganda |
2024-06-05 17:42:17 |
2027-06-05 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
KIYINGI MARTIN
ID:
|
A critical review of [Nature of existence]; to establish "Existential Scope of education", the "Problem of education", "Forms of inquiry” and “Perspectives of knowledge”, in Uganda. A case of selected education policy institutions and Universities in Uganda.
REFNo: SS2573ES
4. To explore possibility of Physical (Truth, Empirical Knowledge and Reality), to alleviate the prevailing and emerging, “Existential” and “Physical” problems; probably the prevailing “Scope of education” is focused at mitigation and adaptation rational consequential [Physical problems (Outcomes)] of own continuous existential Causation and Processing. ,3. To explore how the [Nature of existence] influence Existential (Truth, Knowledge & Reality) and establish if possibility of (Truth, Knowledge and Reality) is limited to only the physical possibility of existence.,2. To explore the “Problem of education” and establish how the [Existential forms of inquiry] based on the [Nature of existence] influence the [Perspectives (Viewpoint) of knowledge]. ,1. To explore the fundamental [Nature of existence], a fundamentalism of [Existential Identity] of all species, the “Scope of education” and basis for respective [Existential forms of inquiry (Sensory response to stimulus)].,
|
Uganda |
2024-06-05 17:39:12 |
2027-06-05 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Cornelius Sendagire
ID: UNCST-2021-R004351
|
Potentially modifiable factors to improve outcomes of mechanically ventilated patients in ICUs in Resource-limited settings (MOTIVATE-ICU)
REFNo: HS4040ES
To assess outcomes associated with tracheostomy timing in IMV patients in LMIC ICUs.,To determine non-modifiable patient-level factors associated with ICU mortality, ICU length of stay and duration of mechanical ventilation among LMIC ICU patients. ,To identify potentially modifiable factors associated with ICU mortality, ICU length of stay and duration of mechanical ventilation among LMIC ICU patients. ,
|
Uganda |
2024-06-05 17:37:52 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|